– Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at NASH Summit in Boston, MA, on April 24th Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients...
The University of Chicago will lead the NRG Oncology Statistics and Data Management Center (SDMC), which is receiving six more years of funding from the National Cancer Institute (NCI). “We are delighted that our institution is providing leadership on coordinating...
Nephure TM enzyme was evaluated vs. placebo in reduction of urinary oxalate associated with food oxalate, and will release results of the study May 4. We are delighted to be presenting our clinical results, which further confirm the efficacy and potency of our...
More drug-coated balloon (DCB) patients were event-free at six months compared to those treated with plain percutaneous transluminal angioplasty (PTA), according to global randomised trial demonstrating safety of a DCB in below-the-knee (BTK) use. London, UK, Thursday...
Oncology trials are becoming increasingly complex owing to the evolution of study designs (platform, basket and umbrella trials). eClinical technology has the capacity to accommodate the complexities of trial management. In this free webinar, learn how to efficiently...
In basket trials, cancers with differing histologies are pooled and the common element is a singular genetic mutation or protein alteration. The trial tests a drug that targets a common biologic process. This ability to assess numerous cancer types with one biomarker...
Email
Text